8MV0 Stock Chart & Stats
€1.41
-€0.15(-8.67%)
At close: 4:00 PM EDT
€1.41
-€0.15(-8.67%)
Day’s Range― - ―
52-Week Range€1.22 - €10.80
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
€31.58M
Enterprise Value€66.16
Total Cash (Recent Filing)€16.22M
Total Debt (Recent Filing)€17.55M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Nov 30, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding22,667,843
10 Day Avg. Volume20
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.84Price Target Upside455.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.35
Revenue Forecast (FY)€37.71M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Gross MarginsRapid revenue expansion combined with a gross margin near 59% indicates meaningful product demand and attractive unit economics. If maintained, this gross-profit base can support investment in commercialization and platform development while improving the potential for operating leverage as the business scales.
First Major CDMO Manufacturing AgreementThe first major CDMO agreement provides external validation for the botanical synthesis platform and creates a pathway beyond the company’s existing consumer products. The planned 20-ton program could add meaningful recurring manufacturing revenue and broaden BioHarvest’s commercial reach over the next several years.
Expanded Platform Partnerships And Technology SupportProgress across saffron and plant-based sweeteners demonstrates that the platform is being applied to multiple bioactive and ingredient opportunities. Milestone funding, retained composition ownership, royalties, and broader collaboration scope could diversify future revenue and increase the technology’s strategic value.
Bears Say
Persistent Losses And Negative Cash GenerationBioHarvest has not yet converted its strong gross margin into sustainable profitability or internally generated cash. Continued operating and free-cash-flow deficits can require financing or balance-sheet support, limiting flexibility to invest in growth and increasing execution risk during commercialization.
Lowered 2026 Revenue And EBITDA GuidanceThe reduced outlook signals that the current commercial ramp is progressing more slowly than previously expected, while operating investment remains elevated. Lower near-term revenue and a wider EBITDA loss could delay breakeven, constrain funding flexibility, and increase dependence on successful CDMO execution.
Rising Debt Alongside Deeply Negative ReturnsAlthough equity has returned to positive territory, rising debt combined with deeply negative returns shows that capital is not yet producing adequate earnings. This weak financial productivity can restrict strategic flexibility, increase obligations while losses continue, and make the path to durable self-funding more difficult.
BioHarvest Sciences News
8MV0 FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was €1.22 and its highest was €10.80 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is €31.58M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s upcoming earnings report date is Nov 30, 2026 which is in 72 days.
How were BioHarvest Sciences’s earnings last quarter?
BioHarvest Sciences released its earnings results on Aug 11, 2026. The company reported -€0.148 earnings per share for the quarter, missing the consensus estimate of -€0.103 by -€0.045.
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Undervalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -0.12.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
BioHarvest Sciences reported an EPS of -€0.148 in its last earnings report, missing expectations of -€0.103. Following the earnings report the stock price went down -25.455%.
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in DE:8MV0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioHarvest Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.84 (455.70% Upside)
€7.84 (455.70% Upside)
Blogger Sentiment
Bullish
DE:8MV0 Sentiment 67%
Sector Average 64%
Sector Average 64%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.
8MV0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced significant strategic progress and validation—most notably the major fragrance CDMO contract, stronger cash position, and government-backed technology grants—against near-term revenue guidance cuts, higher operating expenses, and continued adjusted EBITDA losses. Management is pivoting resources toward higher-margin CDMO opportunities and capacity build-out, accepting lower near-term product revenue (VINIA) in order to pursue longer-term profitability and scale. Key positives are the sizeable contract pipeline and material cash increase; key negatives are reduced 2026 top-line guidance and short-term profitability pressures stemming from reallocated marketing and development spend.View all DE:8MV0 earnings summaries8MV0 Stock 12 Month Forecast
Average Price Target
€7.84
▲(455.70% Upside)